COMMUNIQUÉS West-GlobeNewswire

Notice of annual shareholders’ meeting in Saniona AB

24/04/2018 - 08:00

PRESS RELEASE April 24, 2018 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona [...]

Notification from Oasmia Pharmaceutical AB

24/04/2018 - 08:00

Uppsala, Sweden, April 24, 2018 – Oasmia Pharmaceutical AB hereby issues a notification regarding the issuance of the agenda for EMA’s CHMP meeting April 23 – 26. Instead of the announced oral explanation, Oasmia will [...]

Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1

24/04/2018 - 07:31

Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 Paris - 24 th April 2018 -- Elias Zerhouni, M.D., Head of [...]

Départ à la retraite du Président Monde de la R&D de Sanofi, Elias Zerhouni ; L'entreprise nomme John Reed pour lui succéder à compter du 1er juillet

24/04/2018 - 07:31

Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) Départ à la retraite du Président Monde de la R&D de Sanofi, Elias Zerhouni ; L'entreprise nomme John Reed pour lui succéder à compter du 1 er [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

24/04/2018 - 07:01

REGULATED INFORMATION GHENT, Belgium, 24 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

Targovax ASA: Invitation to first quarter 2018 results presentation Thursday 3 May

24/04/2018 - 07:01

Oslo, Norway, 24 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its first quarter 2018 results on Thursday, 3 May [...]

MDxHealth Provides First Quarter 2018

24/04/2018 - 07:01

NEWS RELEASE REGULATED INFORMATION INTERIM TRADING UPDATE MDxHealth Provides First Quarter 2018 Business Update IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, April 24, 2018 - MDxHealth SA ("MDxHealth, or the "Company [...]

MDxHealth publie ses résultats du premier trimestre 2018

24/04/2018 - 07:01

COMMUNIQUÉ DE PRESSE INFORMATIONS REGLEMENTÉES RAPPORT D'ACTIVITÉS TEMPORAIRE MDxHealth publie ses résultats du premier trimestre 2018 IRVINE, CA, et HERSTAL, BELGIQUE - 07h00 CEST, mardi 24 avril 2018 - MDxHealth SA [...]

argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting

24/04/2018 - 07:01

Eight-week follow-up data show separation of clinical efficacy scores between treatment group and placebo group through the duration of study Total and pathogenic IgG reduction correlates with disease score improvements [...]

Axiom Real-Time Metrics Exhibiting Fusion eClinical Suite at Clinical Operations in Oncology Trials West

24/04/2018 - 01:11

TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics, premier provider of unified eClinical solutions and services, is exhibiting at Clinical Operations in Oncology Trials West on April 24 th and 25 th in [...]

Immuron CEO to Present at RedChip Global Online Growth Conference

24/04/2018 - 00:57

MELBOURNE, Australia, April 23, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ: IMRN ), Australian microbiome biopharmaceutical company focused on developing and commercialising orally delivered targeted [...]

Apellis Pharmaceuticals Announces Closing of Offering of Common Stock

24/04/2018 - 00:20

CRESTWOOD, Ky. and WALTHAM, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS ), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds [...]

Epizyme Provides Update Regarding Tazemetostat Clinical Program

23/04/2018 - 22:45

CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM ), a clinical-stage company developing novel epigenetic therapies, today announced that U.S.-based enrollment of new patients into [...]

Surface Oncology Announces Closing of $119.5 Million Aggregate Financing, Consisting of $108.0 Million Initial Public Offering and $11.5 Million Concurrent Private Placement

23/04/2018 - 22:30

CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (“Surface”), an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment, today announced [...]

Brian Andrews to Succeed Albert White as Chief Financial Officer of The Cooper Companies

23/04/2018 - 22:17

PLEASANTON, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE: COO ) today announced that Brian Andrews has been promoted to Senior Vice President, Chief Financial Officer and Treasurer of The [...]

Natus Confirms Receipt of Notice of Voce Capital’s Intent to Nominate Director Candidates to Replace 50% of the Natus Board

23/04/2018 - 22:11

No Shareholder Action Required at this Time PLEASANTON, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: BABY ) (“Natus” or the “Company”) today confirmed that Voce Capital Management LLC [...]

Genesis HealthCare Sells 51% Stake in Chinese Subsidiary GRS-HS to Riswein Health Industry Investment Co., Ltd

23/04/2018 - 22:05

KENNETT SQUARE, Pa., April 23, 2018 (GLOBE NEWSWIRE) -- Genesis HealthCare (Genesis, or the Company) (NYSE: GEN ), one of the largest post-acute care providers in the United States, today announced that it has signed a [...]

Harvard Bioscience Schedules First Quarter 2018 Conference Call for May 2 at 4:30 PM ET

23/04/2018 - 22:05

HOLLISTON, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO ), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results [...]

ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director

23/04/2018 - 22:05

New Management Structure Further Fuels Strategic Evolution into Consumer-Focused Integrated Nutraceutical Company IRVINE, Calif., April 23, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), an integrated, [...]